Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted

doi:10.1186/cc5786

Critical Care

Volume 11
Issue 3

Viewing options:

Abstract
Full text
PDF (28KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Roberts DM
Roberts JA

on PubMed

Roberts DM
Roberts JA
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Letter

Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted

Darren M Roberts¹^,2 and Jason A Roberts³^,4

¹South Asian Clinical Toxicology Research Collaboration, Medical School, Australian National University, PO Box 5141, Kingston, Australian Capital Territory, Australia, 2604

²Department of Clinical Pharmacology and Toxicology, The Canberra Hospital, PO Box 5141, Kingston, Australian Capital Territory, Australia, 2604

³Burns, Trauma and Critical Care Research Centre, University of Queensland, Level 3 Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield St, Herston QLD Australia 4029

⁴Departments of Intensive Care Medicine and Pharmacy, Level 3 Ned Hanlon Building, Royal Brisbane and Women's Hospital, Butterfield St, Herston QLD Australia 4029

author email corresponding author email

Critical Care 2007, 11:413doi:10.1186/cc5786


Published:	2 May 2007

See related research by Ruelbach et al. http://ccforum.com/content/11/1/R4 and related letter by Brvar and Bunc, http://ccforum.com/content/11/3/415

First paragraph (this article has no abstract)

We read with interest the analysis by Reulbach and colleagues regarding the treatment of neuroleptic malignant syndrome (NMS) [1]. In this analysis, the effect of various treatments on clinical outcomes from 271 single case reports was reviewed. It was concluded that dantrolene does not seem to be the evidence-based treatment of choice for NMS.